Experience
Otsuka Pharmaceutical Co., Ltd.
Apotex Corp. et al
Counsel for Otsuka in Hatch-Waxman cases involving 24 companies seeking to market generic copies of Abilify® following expiration of compound patent covering active ingredient in Abilify®. Only one case still pending following confidential resolutions of all other matters.
Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp. et al, 1:14-cv-01078, -04671, -02982, -07405, -05878, -06398 -08074 -03306, -06890, -05876, -08077, -03168, -07252, -07105 -05537, -03996, -06158, -04508, -04307, -06397, -07106, -01979, -03445; 1:15-cv-0161, -07584, -01585, -07803, -08830, -05109, -07802, -08955, -01716, -01967, -06353, -08305; 1:16-cv-05288, -05400, -05949, -07705 -02475, -02476, -08284, -05743, -00086, -08085, -00555, -00557, -07346, -06067, -00405, -00424, -05688, -09603; 1:17-cv-02754, -00392, D.N.J., Judges Simandle, Williams
Ajinomoto Co., Inc. et al. v. CJ Cheiljedang Corp. et al.
Ajinomoto Company, Inc. et al.
District court ruling maintains patent and regulatory protection of Otsuka’s Abilify®
Otsuka Pharmaceutical Co., Ltd.
Medicis Pharmaceutical Corp. v. Apotex, Inc.
Medicis Pharmaceutical Corp.
Finnegan revives key Jublia® patent at the Federal Circuit
Kaken Pharmaceutical Co., Ltd.; Bausch Health Care
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd.
Senju Pharmaceutical Co.; Bausch + Lomb
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
Otsuka Pharmaceutical Co.
Acorda Therapeutics, Inc. v. Apotex Inc.
Acorda Therapeutics, Inc.
Horizon Pharma v. Dr. Reddy's Laboratories, et al.
Horizon Pharma
SZ DJI Technology Co., Ltd. et al v. Yuneec International Co. Ltd.
SZ DJI Technology Co., Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.